Cargando…

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells

BACKGROUND: CD8 lymphocytes play an important role in the pathogenesis of COPD. Corticosteroids and phosphodiesterase 4 (PDE4) inhibitors are anti-inflammatory drugs used for COPD treatment. Little is known of the combined effect of these drugs on COPD CD8 cells. We studied the effect of corticoster...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grundy, Seamus, Plumb, Jonathan, Kaur, Manminder, Ray, David, Singh, Dave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727404/ https://www.ncbi.nlm.nih.gov/pubmed/26809346 http://dx.doi.org/10.1186/s12931-016-0325-8

Ejemplares similares

Down Regulation of T Cell Receptor Expression in COPD Pulmonary CD8 Cells
por: Grundy, Seamus, et al.
Publicado: (2013)

T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease
por: Kaur, Manminder, et al.
Publicado: (2012)

The effects of corticosteroids on COPD lung macrophages: a pooled analysis
por: Higham, Andrew, et al.
Publicado: (2015)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
por: Singh, Dave, et al.
Publicado: (2018)

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Corticosteroid effects on COPD alveolar macrophages: Dependency on cell culture methodology
por: Higham, Andrew, et al.
Publicado: (2014)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages
por: Lea, Simon R, et al.
Publicado: (2018)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Impacts of anti‐inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation
por: Zheng, Xiao‐Fang, et al.
Publicado: (2021)

Natural Phosphodiesterase-4 Inhibitors with Potential Anti-Inflammatory Activities from Millettia dielsiana
por: Le, Vu Thi Thu, et al.
Publicado: (2023)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Macrophage adaptation in airway inflammatory resolution
por: Kaur, Manminder, et al.
Publicado: (2015)

ABCD of the phosphodiesterase family: interaction and differential activity in COPD
por: Halpin, David MG
Publicado: (2008)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
por: Martin, Clémence, et al.
Publicado: (2021)

Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
por: Watz, Henrik, et al.
Publicado: (2020)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi
por: Khalaf, Rana M., et al.
Publicado: (2017)

Tailoring of corticosteroids in COPD management
por: De Coster, Daan A., et al.
Publicado: (2014)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Morvan's syndrome with anti contactin associated protein like 2 – voltage gated potassium channel antibody presenting with syndrome of inappropriate antidiuretic hormone secretion
por: Sharma, Anjani Kumar, et al.
Publicado: (2016)

LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD
por: Knobloch, Jürgen, et al.
Publicado: (2019)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Additive Effect of Phosphodiesterase Inhibitors in Control of Pulmonary Hypertension after Congenital Cardiac Surgery in Children
por: Peiravian, Farah, et al.
Publicado: (2013)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells
por: Higham, Andrew, et al.
Publicado: (2018)

Anti‐inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone
por: Mose, Kristian F., et al.
Publicado: (2018)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o5mivqrm0jru8m6nari6s29etm